Novo's CagriSema Delivers Superior Weight Loss Versus Tirzepatide in REIMAGINE 5 Trial
Phase 3positiveCagriSematirzepatidePositive
AI Analysis
Summary
Novo Nordisk announced positive Phase 3 topline results from REIMAGINE 5 and REDEFINE 9 trials showing CagriSema (cagrilintide/semaglutide) delivered superior weight loss compared to tirzepatide. The data supports advancement of the investigational once-weekly combination therapy.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
CagriSema delivered superior weight loss versus tirzepatide in REIMAGINE 5 trial
Importance:8/10
Sentiment:
0.85
Phase 3 dataobesity/weight losstopline resultscomparative efficacy
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on September 21, 2026 11:09 PM